Anki Malmborg Hager
Chief Executive Officer since 2014.
Born 1965.
Anki Malmborg Hager has extensive experience from leading positions within the Life Science industry, among others, as CEO of Cantargia AB, XImmune AB and Diaprost AB, Investment Director at LU Bioscience AB and as VP Business Development at Alligator Bioscience AB. She has mainly focused on commercialisation of research from Lund University.
Education: PhD in Immunotechnology, MSc in Chemical Engineering, Pharma MBA.
Shareholding: 373 000 shares and 125 000 warrants (entitles 125 000 new shares).*
Marianne Olsson
Chief Financial Officer since 2016.
Born 1961.
Marianne Olsson has 25 years of experience from Lund University where she has worked as a department economist, economist and most recently as administrative manager at the Department of Immunotechnology. In addition, Marianne has been a member of the Board of the Faculty of Engineering LTH at Lund University, as well as a member of the management and Department Board at the Department of Immunotechnology.
Education: Accounting and executive management training at Lund University.
Shareholding: 50 000 shares and 90 000 warrants (entitles 90 000 new shares).*
Maria Agemark
Chief Operating Officer since 2018.
Born 1974.
Maria Agemark has several years of experience from cell and molecular biology research. She has been with the company since its operational start with a responsibility for setting up and managing the laboratory operations. She has previously conducted postdoctoral research at the Department of Immunotechnology at Lund University.
Education: PhD in Biochemistry and BSc in Molecular Biology.
Shareholding: 25 000 shares and 90 000 warrants (entitles 90 000 new shares).*
Anna Chérouvrier Hansson
Chief Commercial Officer since 2017.
Born 1973.
Anna has extensive experience from marketing, sales and business development from Camurus, Novo Nordisk, Gambro and DuPont among others. In addition, Anna has been a partner at Zitha Consulting, focusing on commercialisation strategy in the pharmaceutical industry and head of Life Science investments at Invest in Skåne.
Education: MSc in European Business Administration and Business Law, BSc in Business Administration.
Shareholding: 10 510 shares (privately and through related parties) and 85 000 warrants (entitles 85 000 new shares).*
Gunilla Grundström
Chief Scientific Officer since 2018.
Born 1968.
Gunilla Grundström is an experienced research manager with more than 10 years of experience from the Life Science and MedTech industry. Prior to her current position, Gunilla held a position as Sr Research Manager at Baxter (Gambro) where she also has held positions as Principal and Sr Research Scientist. In addition, Gunilla Grundström has experience from the pharmaceutical industry as postdoctoral researcher at AstraZeneca.
Education: PhD in Medical Biochemistry, MSc in Chemical Engineering.
Shareholding: –*
Stephen Smith
Intellectual Property Counsel since 2017.
Born 1968.
Stephen Smith is a partner at Potter Clarkson. Over the course of 15 years, he has provided counsel to companies all over Europe, regarding issues concerning intellectual property protection and commercialisation of products among other things. He is a patent attorney and a European patent attorney at the European Patent Institute and a patent attorney at the UK patent institute.
Education: PhD in Neuroscience and MSc in Biochemistry.
Shareholding: –*
Mikael Wahlgren
Deputy Chief Executive Officer since 2018. Chief Legal Officer since 2017.
Born 1965.
Mikael Wahlgren has previously worked as Group General Counsel for Alfa Laval Group as well as Corporate Counsel for several multinational companies. Since 2016, he runs a legal consultancy firm in which he acts as Legal Adviser, Arbitrator and Mediator.
Education: LLM.
Shareholding: 7 500 shares through companies.*
* Last updated 31/12/2018.
